Advanced Medical Solutions vs West Pharmaceutical Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Advanced Medical Solutions Group plc (AMS.LSE)

Q3 202615 Jul – 13 Aug 2026

▲1

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

July 202615 Jul – 13 Aug 2026

▲1

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

Latest15 Jul – 13 Aug 2026

▲1

Shareholders approve H.B. Fuller takeover AMS shareholders voted in favour of H.B. Fuller's recommended cash buyout at meetings on 12 August. That clears a major hurdle, making the deal more likely to complete by year-end and anchoring the share price near the offered terms.
This is the single biggest new event and the main force now setting AMS's price.
Octopus keeps trimming its stake Octopus Investments disclosed its holding fell from 8.66% to 8.28% to 8.07% across July, selling shares each time. The stake is large, but the steady selling suggests it is reducing exposure rather than betting on a higher price.
Shows a major holder's behaviour, a real counterweight to deal optimism.
Broker Investec's routine share dealings Investec, AMS's joint broker, repeatedly bought and sold AMS shares in near-equal amounts around 280p. This is normal market-making tied to its advisory role, not a signal about AMS's health, so it adds little to the bigger picture.
Explains the other recurring disclosure and why it is not a real driver.

Q3 20261 Jul – 1 Aug 2026

▲1

Q2 Earnings Beat and Raised Guidance West Pharmaceutical reported Q2 revenue of $872.3 million, up 13.8%, and adjusted EPS of $2.37, beating estimates. Management raised full-year revenue and EPS guidance, signaling confidence. This directly boosts investor expectations and supports a higher stock price.
This is the most recent and concrete positive catalyst, showing strong financial performance and improved outlook.

July 20261 Jul – 1 Aug 2026

▲1

Q2 Earnings Beat and Raised Guidance West Pharmaceutical reported Q2 revenue of $872.3 million, up 13.8%, and adjusted EPS of $2.37, beating estimates. Management raised full-year revenue and EPS guidance, signaling confidence. This directly boosts investor expectations and supports a higher stock price.
This is the most recent and concrete positive catalyst, showing strong financial performance and improved outlook.

Latest1 Jul – 1 Aug 2026

▲1

Q2 Earnings Beat and Raised Guidance West Pharmaceutical reported Q2 revenue of $872.3 million, up 13.8%, and adjusted EPS of $2.37, beating estimates. Management raised full-year revenue and EPS guidance, signaling confidence. This directly boosts investor expectations and supports a higher stock price.
This is the most recent and concrete positive catalyst, showing strong financial performance and improved outlook.